Can a smart chemo drug outsmart advanced throat cancer?
NCT ID NCT07768189
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-based chemotherapy and immunotherapy. The study compares CRB-701 to standard options like capecitabine, cetuximab, or docetaxel, measuring response rates, survival, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CRB-701, a targeted chemotherapy (antibody-drug conjugate) given by IV every 3 weeks
- What this could lead to
- If successful, CRB-701 could offer a new, more effective treatment option for people with advanced throat cancer who have run out of standard options.
- What could go wrong
- This is an early-stage test in a specific group of patients, and the drug may not prove better than existing treatments or may cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CARCINOMA (OPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florida Cancer Specialists and Research Institute
Orlando, Florida, 32827, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.